Merck News and Resources

Merck KGaA, Darmstadt, Germany has announced the closing of its $3.4 billion (approximately €3 billion) acquisition of SpringWorks Therapeutics, Inc., a U.S.-based biopharmaceutical company focused on rare tumours. The transaction was finalised following regulatory approvals and customary closing conditions. The deal,

Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics, Inc. for $47 per share in cash. The deal values SpringWorks at approximately $3.9 billion, representing a 26% premium to its 20-day volume-weighted average price before transaction speculation began. The

Merck, also known as MSD outside the U.S. and Canada, has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) for the global development, manufacturing, and commercialization of HRS-5346, an investigational oral small molecule Lipoprotein(a) (Lp(a)) inhibitor.

Merck also known as MSD outside the United States and Canada, has inaugurated a $1 billion vaccine manufacturing facility at its Durham, North Carolina, site. The 225,000-square-foot expansion aims to enhance the company’s production capacity and technological capabilities. This investment

Merck, a science and technology company, has introduced the beta version of its innovative M-Trust platform, designed to enhance product traceability, safety, and authenticity. The platform aims to address the growing challenges faced by industries in ensuring product quality and

Merck, operating as MSD outside the US and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, have entered into a global licensing agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the terms of the agreement,

Merck has completed the acquisition of Modifi Bio, a startup developed from Yale University, for an upfront payment of $30 million. The deal could ultimately be worth up to $1.3 billion, depending on future milestone payments associated with the company’s

Merck, has been awarded the EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary Materials (PAMs) across its global Cell Culture Media (CCM) production sites. This certification is significant as it marks the first time a company in the